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Abstract
Purpose A region of chromosome 22 which includes
APOL1 and MYH9 genes was recently identified as a
risk locus for non-diabetic forms of kidney disease,
including idiopathic and HIV-associated focal seg-
mental glomerular sclerosis and kidney disease clin-
ically attributed to hypertension among African
Americans. The purposes of the current study were,
therefore, to examine the frequency of these variants
and to determine whether they are associated with
chronic kidney disease (CKD) among native Africans.
Methods To investigate the possible evidence of
association between variants in these genes and non-
diabetic CKD among West Africans, we performed a
case/control analysis in a sample of 166 Nigerians
without history of European admixture. Our study
included a total of 9 variants on APOL1 (n = 4) and
MYH9 (n = 5) genes.
Results We observed significantly strong associa-
tions with previously reported APOL1 variants
rs73885319 and rs60910145, and their two-allele
‘‘G1’’ haplotype (P \ 0.005). We did not observe
significant evidence of association between non-dia-
betic CKD and any of the MYH9 variants or haplotypes
after accounting for multiple testing in our sample.
Conclusions In conclusion, APOL1 risk variants are
associated with non-diabetic forms of CKD among
Nigerians of Yoruba ethnicity. Further information on
APOL1/MYH9 variants may lead to screening pro-
grams, which could lead to earlier detection and
interventions for non-diabetic kidney disease.
Keywords Chronic kidney disease  APOL1 
MYH9  Genetic renal disease
Introduction
The lifetime risk of end-stage kidney disease (ESKD)
among African Americans is threefold higher than that
among whites [1]. Differences in access to care and
other socioeconomic factors do not entirely account for
the markedly higher rates of ESKD among African
Americans which suggests a possible role for genetic
factors [1–6]. Recently, a region of chromosome 22,
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which includes APOL1 and MYH9 genes, was identi-
fied using mapping by admixture disequilibrium as a
risk locus for non-diabetic forms of kidney disease,
including idiopathic and HIV-associated focal seg-
mental glomerular sclerosis (FSGS) and kidney dis-
ease clinically attributed to hypertension [7–9].
Genetic variants in the region show very strong
associations with non-diabetic kidney disease. Specif-
ically, a two-allele haplotype termed ‘‘G1’’ consisting
of two non-synonymous coding variants rs73885319
(S342G) and rs60910145 (I384M) along with
rs71785313—a 6 base pair deletion termed ‘‘G2’’ and
close to G1 in exon 5 of APOL1 [10, 11]—is likely to
account for the majority of risk of non-diabetic kidney
disease associated with the variants in this region, but
the role of MYH9 variants in non-diabetic kidney
disease risk remains controversial [7]. Regardless,
variants in the region are more common in individuals
of African descent compared with those of European
descent [10, 11]. The fact that these variants are absent
or less common in other populations has been used to
explain the non-replication of these associations in
non-African descent populations. The purposes of the
current study were, therefore, to examine the frequency
of these variants and to determine whether they are
associated with CKD among native Africans.
Subjects and methods
Study participants and phenotype measurements
The source population for both cases and controls was
participants in the Genetics of Hypertension in Blacks
study, an ongoing project examining genetic variants
for blood pressure among adults from the Yoruba
tribe. Participants in the current analyses included 88
and 81 adults with and without non-diabetic kidney
disease, respectively. Participants were recruited from
the University College Hospital General Medicine and
Nephrology clinics, University of Ibadan, Nigeria.
The project was reviewed and approved by the
Institutional Review Board at the Loyola University
Chicago Stritch School of Medicine, Maywood, IL
and the Joint Ethical Committee of the University of
Ibadan/University College Hospital, Ibadan, Nigeria.
The consent process was presented in English or
Yoruba, and written informed consent was obtained
from all participants.
Cases were defined as individuals of the Yoruba
tribe aged 16–70 years with all stages of chronic
kidney disease (CKD) of at least 3 months duration
who met criteria for non-diabetic CKD clinically
associated with long-standing hypertension, or CKD
in the presence of proteinuria (Proteinuric CKD) or
CKD associated with HIV. Proteinuric CKD was
defined as presence of spot urine protein/creatinine
C2 g/g in the absence of red blood cell (RBC) casts or
hematuria on urine microscopy or urinalysis and
absence of known causes for CKD such as parasitic or
other infections or diabetes. Clinically diagnosed
hypertension-associated CKD was based on history
or clinical evidence of long-standing hypertension
(e.g., electrocardiogram evidence of left ventricular
hypertrophy) and a spot urine protein/creatinine ratio
\2 g/g, in the absence of other known causes for
CKD, consistent with the African American Study of
Kidney Disease criteria [12]. CKD associated with
HIV was defined as a positive HIV test and absence of
other known causes for CKD including diabetes and
parasitic diseases. Women who were pregnant, per-
sons with diabetes mellitus, sickle cell disease,
hepatitis B or C, acute kidney injury, or other terminal
illnesses such as cancer were excluded. Individuals
with CKD were recruited by nephrologists at the
University College Hospital. Patients were evaluated
by physicians in the Nephrology clinic. The clinical
exam and laboratory studies included three serial
blood pressure measurements using an automated
device (Omron HEM-412C) previously evaluated in
our field settings [13], anthropometric measures, a
complete blood count and metabolic panel, electro-
cardiogram (ECG), testing for HIV and hepatitis B,
urinalysis with microscopy and a bilateral kidney
ultrasound when possible. All laboratory analyses in
cases were completed at the University College
Hospital Laboratory as part of routine clinical workup.
Controls consisted of normotensive individuals
(BP \ 140/90 in the absence of anti-hypertensive
medication use) of the Yoruba tribe without evidence
of kidney disease (serum creatinine\1.4 and\1.2 mg/dl
in men and women, respectively, and spot urine
albumin/creatinine ratio \30 mg/g). All controls had
standardized physical exams including three serial
blood pressure measurements using the same device as
used for the cases; fasting blood samples and a spot
urine specimen were also obtained. Serum creatinine
was measured in the control specimens at Fairview
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Laboratory in Minnesota by rate reflectance spectro-
photometry using thin film adaptation of the creatinine
amidinohydrolase method on the Vitros analyzer
(Johnson and Johnson Clinical Diagnostics, Roches-
ter, NY). The laboratory analytic coefficient of
variation was 2.2 %.
Genotyping and quality assessment
Genotyping was carried out on genomic DNA from 88
non-diabetic CKD subjects and 81 non-CKD subjects
randomly selected from among the controls described
above. The genotyping was performed at the Charles
R. Bronfman Institute for Personalized Medicine
(Mount Sinai School of Medicine, New York, NY),
using a custom FluidigmTM 96.96 array platform and
ABI TaqMan SNP genotyping assays. The assays were
originally selected for 96 published disease-associated
single nucleotide polymorphisms (SNPs) and included
4 SNPs on APOL1 and 6 SNPs on MYH9 genes which
have been reported to be associated with kidney
disease. The assays also included variants associated
with liver disease, type 2 diabetes or drug response.
Standard quality control procedures were applied to
the genotype data using all SNPs on the chip. As part
of the procedures, 3 samples (1 case and 2 controls)
and 2 SNPs with proportion of missing genotypes
greater than 0.1 were filtered out. We also filtered out
SNPs with minor allele frequency less than 0.05
(n = 23) or failing Hardy–Weinberg equilibrium test
at 0.01 (n = 3). The final 68 SNPs that passed quality
control included 9 of the 10 APOL1/MYH9 variants.
Since the objective of the current analysis was to
examine the association between previously reported
kidney disease–associated SNPs and CKD in a sample
of Nigerians, subsequent screening for associations
with CKD was therefore restricted to just the variants
on APOL1 (rs9622363, rs73885319, rs60910145 and
rs71785313) and MYH9 (rs11912763, rs2032487,
rs4821481, rs5750248 and rs5750250) genes.
Statistical analyses
To test for associations between CKD status and each
single SNP, we fitted logistic regression models in
which each SNP was presented as a predictor variable
whose values were equal to the number of copies of the
minor allele (0, 1, 2) (i.e., additive mode), or presence
of at least one copy of the minor allele (0, 1) (i.e.,
dominant mode) or presence of two copies of the
minor allele (0, 1) (i.e., recessive mode). The fitted
model, which included sex and age as covariates, can
be represented as: logit[pr(D = 1)] = a ? b1G ?
b2sex ? b3age, where D denotes CKD affection
status; G denotes SNP coded as additive, dominant
or recessive; b denotes the corresponding coefficient
for each variable in the model (SNP, sex or age), and
its exponential is the corresponding odds ratio. To
account for multiple comparisons, the statistical
significance of each association test was empirically
derived by permuting the data set 10,000 times.
To explore the possible associations between CKD
status and various joint allelic configurations of
multiple SNPs, we performed haplotype association
analysis of the APOL1 and MYH9 SNPs. We used the
software Haploview [14] to compute the estimates of
linkage disequilibrium (LD) for each pair of SNPs by
the standard D-prime method[15] and to determine
the haplotype blocks—regions with no evidence of
historical recombination events, but significant level
of LD. The haplotype blocks were defined by the
four-gamete test [16, 17] as implemented in Haplo-
view. Analysis included all haplotypes with frequen-
cies of at least 10 % within the constructed blocks
and also the two-allele haplotypes consisting of
rs73885319 and rs60910145 that included G1. All the
haplotypes were individually tested for association
with CKD by using logistic regression models as
described above for tests of genotype association.
Age and gender were adjusted for in each haplotype–
phenotype analysis.
Results
After excluding participants whose genotype data did
not pass quality control, the study sample consisted of
a total of 166 subjects (87 cases and 79 controls). The
descriptive characteristics of the cases and controls are
presented in Table 1. Among both cases and controls,
approximately half were women. On average, the
CKD subjects tended to be older (42.1 vs. 35.2 years),
heavier (23.2 vs. 21.9 kg/m2) and have higher blood
pressure (systolic: 136.6 vs. 111.6 mm Hg) when
compared with the non-CKD controls. Among the 87
CKD subjects, the physician-reported diagnosis of
kidney disease was proteinuric CKD in 35 (40.2 %),
HIV nephropathy in 8 (9.2 %) and clinically attributed
Int Urol Nephrol (2013) 45:485–494 487
123
hypertensive CKD in 44 (50.5 %). All the CKD
subjects had a negative hepatitis B surface antigen test
within 30 days of enrollment in the study. All but 3
cases had stage 5 CKD (1 with proteinuric CKD and 2
with CKD clinically attributed to hypertension.
The frequencies of the risk allele of the 9 APOL1/
MYH9 variants among the cases and controls are listed
in Table 2. In the current analyses, the coded alleles are
the same as the minor alleles of the variants. For any
variant with reported odds ratio (OR) greater than 1.0,
the coded minor allele is also the risk or disease
susceptibility allele. As would be expected, coded risk
alleles tended to be more frequent in cases than in
controls, for example, 0.442 versus 0.266 and 0.500
versus 0.301 for rs73885319 and rs60910145, respec-
tively. The variant rs71785313, which is an APOL1
insertion/deletion, had the least frequent minor allele
(0.105) in both cases and controls. Results of the
covariate-adjusted case/control analyses are also pre-
sented in Table 2 for additive, dominant and recessive
genetic modes of association. We observed significant
associations for two APOL1 SNPs—rs73885319 and
rs60910145 under all three genetic modes of asso-
ciation. Both variants have larger effects under the
recessive mode (odds ratios: 3.85 and 3.12 for
rs73885319 and rs60910145, respectively) when com-
pared with the additive or dominant mode. The two
variants are in almost perfect linkage disequilib-
rium (D-prime = 1.00, r2 = 0.82) and as such, when
adjusted for either one, the association for the other
disappeared.
The haplotype blocks formed by the APOL1/MYH9
variants are displayed in Fig. 1. There were two blocks
consisting of three APOL1 SNPs and four MYH9 SNPs,
respectively. Two SNPs, rs71785313 on APOL1 and
rs11912763 on MYH9, were not included in any of the
blocks. The APOL1 block thus included rs9622363,
rs73885319 and rs60910145, and the MYH9 block
included rs2032487, rs4821481, rs5750248 and
rs5750250. There were a total of five haplotypes each
with a frequency of at least 0.10 (Fig. 1). The results of
the covariate-adjusted haplotype associations are pre-
sented in Table 3. We also present the results for the
two-allele haplotypes of rs73885319 and rs60910145
that included the previously reported G1 haplotype.
Haplotype frequencies ranged between 0.217 and
0.675 in the study sample. The association results
indicate that the G–A–G haplotype of the APOL1 SNPs
(rs9622363–rs73885319–rs60910145) is a significant
risk factor for CKD under any mode of association. The
ORs are 2.26 (p = 0.005), 2.54 (p = 0.023) and 3.79
(p = 0.041) for the additive, dominant and recessive
modes of association, respectively, after correction for
multiple comparisons. Similarly, the two-allele haplo-
types of rs73885319 and rs60910145 otherwise termed
G1, demonstrated strong levels of association with
CKD. The ORs for the G1:rs73885319–rs60910145
(A–G) haplotype are 2.25 (p = 0.006), 2.52
(p = 0.025) and 3.80 (p = 0.041) for the additive,
dominant and recessive modes of association, respec-
tively. The crude association [OR, 2.67(95 % CI,
0.79–8.97)] with the compound risk heterozygote state
among subjects heterozygous (10 cases and 5 controls)
for both the G1:A–G and G2:D risk alleles and subjects
(21 cases and 28 controls) without any of the risk
alleles was not significant (P = 0.143). On the
other hand, the G–T haplotype of G1:rs73885319–
rs60910145 indicated significant protective
Table 1 Descriptive characteristics of study subjects
Non-diabetic CKD cases (N = 87) Controls (N = 79) All (N = 166)
No. of females (%) 41 (47 %) 39 (49 %) 80 (48 %)
Age (years) 42.1 ± 16.9 35.2 ± 8.2 38.8 ± 13.9
Body weight (kg) 61.6 ± 11.1 59.8 ± 10.8 60.8 ± 11.0
Height (m) 1.6 ± 0.1 1.7 ± 0.1 1.6 ± 0.1
Body mass index (kg/m2) 23.2 ± 4.6 21.9 ± 4.2 22.6 ± 4.4
Systolic blood pressure (mm Hg) 136.6 ± 31.0 111.6 ± 10.0 124.7 ± 26.6
Diastolic blood pressure (mm Hg) 88.1 ± 20.7 66.9 ± 6.1 78.0 ± 18.8
CKD chronic kidney disease
Data presented as mean ± standard deviation
 Values are significantly different (P \ 0.05) between cases and controls
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association with CKD under the additive (OR = 0.49,
p = 0.005), dominant (OR = 0.40, p = 0.025) and
recessive (OR = 0.32, p = 0.014) modes. The impli-
cation of this is a significantly high CKD risk for those
carrying zero copies of the G1:G–T haplotype—with
an OR as high as 3.13 (p = 0.014). We did not observe
significant evidence of association between any of the
MYH9 haplotypes and CKD after accounting for
multiple testing (Table 3).
Discussion
In this study, we report the findings from a case/control
association analysis of non-diabetic chronic kidney
disease and variants in APOL1 and MYH9 genes in an
African sample from southwest Nigeria. APOL1 and
MYH9 variants are associated with non-diabetic CKD
among African Americans [7–9, 11, 18, 19] and
Hispanic Americans [20]. The purpose of our study
was to investigate the possible evidence of association
between these variants and non-diabetic CKD in a
sample of Africans of the Yoruba tribe without history
of European admixture. We replicated association
with APOL1 gene variants previously reported among
African Americans and Hispanic Americans [10, 11].
We observed significant associations with two APOL1
variants and their haplotypes. The strength of the
association between the two-allele haplotype of
APOL1 variants rs60910145 and rs73885319 (G1)
Fig. 1 Plot of linkage
disequilibrium between
SNPs in APOL1/MYH9
region (top) and their
haplotypes (bottom)
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and non-diabetic CKD in the current study is about
half of the sevenfold-increased odds of hypertensive
kidney disease reported among African Americans
carrying multiple copies of APOL1 risk alleles [10].
Stronger associations have been reported with HIV
nephropathy [11, 19]. Since sample size only affects
statistical significance of estimates and not the
strength of the estimates, the apparent attenuation of
the observed association when compared to previous
findings among African Americans cannot be attrib-
uted to sample size. To confirm this, we investigated
how much power the current study had to detect
significant association between a variant with risk
allele frequency at least similar to that observed for
G1:A–G (i.e., 0.360), a genetic effect of at least 3.0
under a population risk of 0.00001. Using the software
QUANTO[21], we estimated that the current study has
at least 80 % power to detect association under
recessive mode and over 90 % power under dominant
or additive mode.
We noted that the risk allele in the current sample is
different for rs73885319 than previously reported
[11]. It should be noted that risk allele frequencies for
this variant have been observed to differ substantially
across African populations [11]. In an African popu-
lation sample set consisting of 676 samples from 12
African populations that included Cameroon (2 ethnic
groups), Congo, Ethiopia (4 ethnic groups), Ghana
(2 ethnic groups), Malawi, Mozambique and Sudan,
Tzur et al. [11] observed that risk allele frequencies
differ between groups from same country and also
across the populations. In the Bulsa and Asante
populations of Ghana, the frequencies are respectively
0.11 and 0.41, whereas for the Ethiopian groups the
frequencies were zero. It is possible that non-diabetic
kidney disease risk is not mediated by this variant but
rather by other alleles in linkage disequilibrium with
the variant or the haplotype G1. As for MYH9, we did
not find significant association between non-diabetic
CKD and any variant or haplotype after correction for
multiple testing. A previous study indicated that G1
and G2 are in strong LD with variants in MYH9 [10],
and most of the association previously attributed to
MYH9 variants or haplotypes with CKD is explained
by LD with APOL1 variant rs73885319 [10, 11]. In the
present study, we observed reduction in the strength of
CKD association with MYH9 variants when we
accounted for the APOL1 variants by conditioning
on either rs73885319 or rs60910145 in the regression
models fitted for each of the MYH9 variants. We note
that the observed low LD (r2 B 0.12) between APOL1
and MYH9 variants in our study sample may have
contributed to the observed non-significant association
of MYH9 variants with CKD.
Among African Americans, the frequency of the
APOL1 risk allele is around 0.33 with the high-risk
genotype frequency being about 0.11 [22]. Previous
studies have reported strong associations with APOL1
risk alleles G1 (rs73885319 and rs60910145) and G2
(rs71785313) in an autosomal recessive fashion.
Inheritance of 2 APOL1 risk alleles (G1 and G1, G1
and G2, or G2 and G2) increases the risk of non-
diabetic kidney disease by over sevenfold. For HIV
nephropathy, associations may exceed 30-fold [22]. In
this study, we noted a fairly strong association
between the G1 risk allele in a recessive model but
no association was noted between G2 and non-diabetic
kidney disease. This is likely due, in part, to the effect
of sample size and the observed low minor allele
frequency for G2. It is also possible that differences in
the association between APOL1 variants and CKD in
this study could, in part, be due to misclassification of
cases or gene 9 environment interactions but these
interpretations remain speculative.
In this study, the strength of the associations
between 2 SNPs included in the MYH9 E1 risk
haplotype and non-diabetic kidney disease, though not
significant after adjusting for multiple comparisons,
was similar to associations reported in cases with end-
stage kidney disease clinically attributed to hyperten-
sion [18]. The MHY9 E1 risk haplotype consists of 4
SNPs (rs4821480, rs2032487, rs4821481 and
rs3752462); robust associations have been docu-
mented in several studies between the E1 haplotype
and non-diabetic kidney disease including idiopathic
and HIV-associated FSGS and CKD clinically attrib-
uted to hypertension [8, 9, 18, 20]. APOL1 variants are
in strong linkage disequilibrium with MYH9 variants
[7], and it remains controversial whether MYH9
variants play a direct role in kidney disease risk [23,
24].
Due to limited resources and poor access to
healthcare for non-urban areas of Nigeria, many
patients who present for diagnostic workup and
treatment of kidney disease do not undergo kidney
biopsy in Ibadan. Diagnosis is typically based on
patient’s history, physical exam and laboratory test-
ing. Misclassification of kidney disease is likely in this
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sample. However, diabetes prevalence is very low in
Nigeria [25, 26], and patients with evidence of diabetic
kidney disease as determined by the treating physician
were excluded from participation in study. The small
sample size limited the ability to determine associa-
tions with specific types of CKD such as hypertensive
CKD or focal segmental glomerulosclerosis. How-
ever, even with the small sample, fairly strong
associations were noted with APOL1 variants and
the haplotype G1. The associations between APOL1
variants and non-diabetic CKD among Nigerians of
the Yoruba tribe demonstrate that the impact of these
genetic factors on CKD risk appear to be independent
of the environment. Diet, lifestyle and social structure
are dramatically different in Nigeria compared to the
United States and other industrialized countries.
Hypertension, diabetes and obesity prevalence are
markedly lower in Nigeria compared to the African
American population [25–29]. Despite these differ-
ences, APOL1 variants are associated with non-
diabetic CKD in this population.
The discovery of the APOL1/MYH9 chromosomal
22 region as a region harboring genetic variants for non-
diabetic CKD risk may be very important. It is possible
that further delineation of the role of MYH9 and APOL1
variants may lead, in the future, to improved screening
programs, prevention strategies and clinical interven-
tions for CKD, one of the most common end-organ
causes of morbidity and mortality worldwide. The
perceived public health importance of these genetic
variants is demonstrated by a patent application by the
National Institutes of Health for these variants [30].
This study demonstrates that these variants are also
operative for non-diabetic kidney disease risk among
Nigerians of the Yoruba tribe. Data suggest that the G1
and G2 variants in the APOL1 region emerged in this
population several thousand years ago as a result of
conferring protection from Trypanosoma brucei rho-
desiense [10, 31], a story very similar to the rise in
frequency of the sickle cell trait as a result of resistance
to certain forms of malaria [32].
Conclusions
In conclusion, APOL1 risk variants are associated with
non-diabetic forms of CKD among Nigerians of
Yoruba ethnicity. Further information on APOL1/
MYH9 variants may lead to screening programs which
could lead to earlier detection and interventions for
non-diabetic kidney disease.
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